Allogene Other Liab vs Net Invested Capital Analysis
ALLO Stock | USD 3.01 0.03 1.01% |
Allogene Therapeutics financial indicator trend analysis is way more than just evaluating Allogene Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Allogene Therapeutics is a good investment. Please check the relationship between Allogene Therapeutics Other Liab and its Net Invested Capital accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Allogene Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Allogene Stock, please use our How to Invest in Allogene Therapeutics guide.
Other Liab vs Net Invested Capital
Other Liab vs Net Invested Capital Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Allogene Therapeutics Other Liab account and Net Invested Capital. At this time, the significance of the direction appears to have pay attention.
The correlation between Allogene Therapeutics' Other Liab and Net Invested Capital is -0.74. Overlapping area represents the amount of variation of Other Liab that can explain the historical movement of Net Invested Capital in the same time period over historical financial statements of Allogene Therapeutics, assuming nothing else is changed. The correlation between historical values of Allogene Therapeutics' Other Liab and Net Invested Capital is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Liab of Allogene Therapeutics are associated (or correlated) with its Net Invested Capital. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Invested Capital has no effect on the direction of Other Liab i.e., Allogene Therapeutics' Other Liab and Net Invested Capital go up and down completely randomly.
Correlation Coefficient | -0.74 |
Relationship Direction | Negative |
Relationship Strength | Weak |
Other Liab
Net Invested Capital
The total amount of capital invested in a company, including both equity and debt, minus any cash or cash equivalents.Most indicators from Allogene Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Allogene Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Allogene Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Allogene Stock, please use our How to Invest in Allogene Therapeutics guide.As of the 17th of May 2024, Sales General And Administrative To Revenue is likely to grow to 792.18, while Selling General Administrative is likely to drop about 61.1 M.
2021 | 2022 | 2023 | 2024 (projected) | Interest Income | 1.7M | 4.6M | 14.8M | 15.5M | Net Interest Income | 1.7M | 4.6M | 14.8M | 9.2M |
Allogene Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Allogene Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Allogene Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 717.8M | 1.2B | 1.0B | 817.1M | 642.8M | 820.0M | |
Other Current Liab | 23.8M | 42.0M | 34.3M | 33.7M | 24.3M | 27.5M | |
Total Current Liabilities | 33.1M | 94.3M | 48.2M | 54.5M | 37.1M | 46.6M | |
Total Stockholder Equity | 629.0M | 1.1B | 916.4M | 665.9M | 512.2M | 708.1M | |
Net Tangible Assets | 628.9M | 1.1B | 916.4M | 665.9M | 765.8M | 732.1M | |
Retained Earnings | (396.1M) | (646.3M) | (903.3M) | (1.2B) | (1.6B) | (1.5B) | |
Accounts Payable | 9.3M | 10.4M | 10.3M | 13.9M | 5.9M | 9.7M | |
Cash | 588.9M | 1.0B | 809.5M | 576.5M | 83.2M | 79.0M | |
Non Current Assets Total | 173.2M | 382.7M | 229.2M | 288.3M | 183.7M | 245.6M | |
Non Currrent Assets Other | 8.9M | 14.6M | (322.1M) | 32.7M | 16.9M | 17.7M | |
Common Stock Total Equity | 121K | 124K | 140K | 142K | 163.3K | 121.7K | |
Common Stock Shares Outstanding | 101.1M | 120.4M | 135.8M | 143.1M | 156.9M | 125.7M | |
Short Term Investments | 355.4M | 644.6M | 284.0M | 455.4M | 365.5M | 388.4M | |
Non Current Liabilities Total | 55.7M | 53.9M | 74.1M | 96.7M | 93.5M | 65.2M | |
Other Stockholder Equity | 1.0B | 1.7B | 1.8B | 1.9B | 2.1B | 1.4B | |
Total Liab | 88.8M | 148.2M | 122.2M | 151.2M | 130.6M | 111.8M | |
Net Invested Capital | 629.0M | 1.1B | 916.4M | 665.9M | 512.2M | 708.1M | |
Long Term Investments | 63.2M | 204.2M | 352.2M | 72.0M | 3.6M | 3.5M | |
Total Current Assets | 544.6M | 845.1M | 809.5M | 528.8M | 459.1M | 574.4M | |
Net Working Capital | 511.5M | 750.8M | 423.1M | 474.3M | 422.0M | 474.6M | |
Common Stock | 124K | 140K | 142K | 144K | 169K | 136.1K | |
Short Long Term Debt Total | 51.3M | 53.8M | 69.9M | 95.1M | 95.1M | 73.3M | |
Other Liab | 4.4M | 3.1M | 4.1M | 1.6M | 1.4M | 1.3M | |
Property Plant And Equipment Net | 100.9M | 160.1M | 181.0M | 196.4M | 163.2M | 154.6M | |
Net Debt | (537.5M) | (978.3M) | (739.6M) | (481.3M) | 12.0M | 12.6M | |
Other Assets | 8.9M | 263.9M | 16.1M | 16.9M | 19.4M | 18.4M | |
Cash And Short Term Investments | 588.9M | 1.0B | 809.5M | 576.5M | 448.7M | 556.9M | |
Net Receivables | 2.4M | 2.8M | 6M | 3.3M | 3.8M | 3.9M | |
Liabilities And Stockholders Equity | 717.8M | 1.2B | 1.0B | 817.1M | 642.8M | 695.7M | |
Capital Lease Obligations | 51.3M | 53.8M | 69.9M | 101.1M | 95.1M | 74.4M | |
Inventory | (60.7M) | (207.0M) | (20.0M) | (62.5M) | (71.8M) | (75.4M) | |
Other Current Assets | 14.0M | 17.2M | 14.0M | 11.5M | 10.4M | 13.3M | |
Property Plant And Equipment Gross | 56.4M | 160.1M | 123.0M | 233.3M | 214.3M | 145.9M | |
Accumulated Other Comprehensive Income | 1.1M | 268K | (2.6M) | (9.9M) | (955K) | (1.0M) | |
Capital Stock | 124K | 140K | 142K | 144K | 169K | 154K | |
Non Current Liabilities Other | 4.4M | 53.9M | 74.1M | 1.6M | 5.2M | 4.9M | |
Property Plant Equipment | 100.9M | 118.8M | 123.0M | 196.4M | 225.9M | 127.8M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Allogene Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Allogene Stock, please use our How to Invest in Allogene Therapeutics guide.You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Complementary Tools for Allogene Stock analysis
When running Allogene Therapeutics' price analysis, check to measure Allogene Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Allogene Therapeutics is operating at the current time. Most of Allogene Therapeutics' value examination focuses on studying past and present price action to predict the probability of Allogene Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Allogene Therapeutics' price. Additionally, you may evaluate how the addition of Allogene Therapeutics to your portfolios can decrease your overall portfolio volatility.
CEOs Directory Screen CEOs from public companies around the world | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |
Is Allogene Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Allogene Therapeutics. If investors know Allogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Allogene Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.78) | Revenue Per Share 0.001 | Quarterly Revenue Growth (0.27) | Return On Assets (0.27) | Return On Equity (0.55) |
The market value of Allogene Therapeutics is measured differently than its book value, which is the value of Allogene that is recorded on the company's balance sheet. Investors also form their own opinion of Allogene Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Allogene Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Allogene Therapeutics' market value can be influenced by many factors that don't directly affect Allogene Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Allogene Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Allogene Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Allogene Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.